S&P 500 slips, but losses kept in check as Nvidia climbs ahead of results
Investing.com - Twist Bioscience reported on Friday fourth quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Twist Bioscience announced earnings per share of $-0.91 on revenue of $57.3M. Analysts polled by Investing.com EPS of $-1.27 on revenue of $56.78M.
Twist Bioscience 's are down 67% and is trading at $26.00 , still down 78.77% from its 52 week high of $119.65 set on Thursday, November 18, 2021.
Twist Bioscience shares gained 2.36% to trade at $26.00 in pre-market trade the report.
Twist Bioscience follows other major Healthcare sector earnings this month
Twist Bioscience's report follows an earnings beat by Eli Lilly on Tuesday, November 1, 2022, who reported EPS of $1.98 on revenue of $6.94B, EPS of $1.91 on revenue of $6.91B.
Pfizer had beat expectations on Tuesday, November 1, 2022 with third quarter EPS of $1.78 on revenue of $22.6B, for EPS of $1.44 on revenue of $21.33B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar